Does Insurance Cover Semaglutide or Wegovy? The Real Answer in 2026

Insurance coverage for GLP-1 medications is one of the most common questions patients have — and one of the most frustrating to answer. The short version: it depends heavily on your specific plan, diagnosis, and employer. The longer version is worth understanding if you're navigating this.

The Basic Coverage Landscape

Ozempic (semaglutide for diabetes): Generally better coverage. Most commercial insurance plans and Medicare Part D cover Ozempic when prescribed for type 2 diabetes. The key word is "prescribed for diabetes" — coverage often requires a T2D or A1C threshold.

Wegovy (semaglutide for obesity): Coverage is worse and more variable. Wegovy is FDA-approved specifically for chronic weight management (BMI ≥30, or ≥27 with a weight-related condition). But many plans still exclude obesity drugs outright or require extensive prior authorization.

Mounjaro/Zepbound (tirzepatide): Mounjaro (diabetes) tends to have better coverage than Zepbound (obesity) — same drug, different FDA indication, different insurance treatment. Zepbound has improved Medicaid coverage in some states since 2024.

Why Coverage Is Inconsistent

Employers opt out. Most commercial insurance plans are self-insured by employers, who decide what the formulary includes. Many employers have explicitly excluded GLP-1 obesity drugs due to cost — they're among the most expensive drug classes by plan spend. If your employer opted out, your plan won't cover it regardless of what your physician recommends.

The obesity vs. diabetes distinction. Insurers frequently cover the same molecule (semaglutide) for diabetes and deny it for obesity. This is a coverage policy choice, not a clinical one — the drug works identically, but the ICD-10 code on the prescription determines reimbursement.

Prior authorization requirements. Even when plans cover GLP-1s, they typically require prior auth: documented BMI, comorbidities, failed attempts at diet/exercise, sometimes a 90-day supervised diet program. This creates months of delay for many patients.

Medicare's evolving position. Medicare Part D historically excluded weight loss drugs. The Inflation Reduction Act created pathways for Medicare coverage of Wegovy starting in 2026 for patients with established cardiovascular disease (following the SELECT trial data). This is a significant expansion, but it's limited to cardiovascular indication, not obesity alone.

How to Check Your Coverage

1. Call the member services number on your insurance card. Ask specifically: "Is Wegovy (semaglutide, NDC 0169-4120-11) covered under my plan? What are the prior authorization requirements?"

1. Check your plan's formulary. Most insurance portals have a drug search — look under Tier 3 or Specialty.

1. Ask your doctor's office. Practices that prescribe GLP-1 medications regularly often have staff who know the prior auth requirements for major local plans.

1. GoodRx and manufacturer programs. Even with insurance, GoodRx coupons can sometimes be cheaper than your copay for generics. Novo Nordisk's NovoCare program offers Wegovy savings for qualifying patients.

If You're Denied

Step 1: Request a prior authorization. If your physician hasn't submitted one yet, start there. Provide documentation: BMI, weight-related comorbidities (hypertension, sleep apnea, prediabetes), prior weight loss attempts.

Step 2: Appeal the denial. Insurance denials are appealable. The success rate for GLP-1 appeals with proper clinical documentation is meaningful — it's worth doing. Your physician's office can submit a letter of medical necessity.

Step 3: Try the diabetes pathway (if applicable). If you have prediabetes or T2D, Ozempic with a diabetes diagnosis code often has better coverage than Wegovy for the same molecule.

Step 4: Consider compounded semaglutide. This is where the math changes for many patients.

The Compounded Semaglutide Option

Compounded semaglutide isn't covered by insurance — but it's dramatically cheaper than branded options without insurance.

• Branded Wegovy without insurance: $1,300–$1,500/month
• Compounded semaglutide from providers like Marrow: $199–$299/month

Insurance coverage that requires months of prior auth, appeals, and ongoing cost-sharing may not be worth the time investment compared to compounded alternatives at this price point. Many patients with insurance find that their effective out-of-pocket cost (after copay, deductible, step therapy requirements) still exceeds $200/month.

The HSA/FSA Question

GLP-1 medications prescribed by a physician for obesity or diabetes are eligible for HSA and FSA reimbursement. This is confirmed by IRS guidance — weight loss treatments prescribed to treat obesity (a diagnosed condition) qualify. Compounded semaglutide is included when obtained with a valid prescription.

If you have an HSA or FSA, using those pre-tax dollars for GLP-1 medications is straightforward — no insurance approval needed.

What's Likely Coming

Coverage is expanding. The SELECT trial data showing semaglutide's 20% reduction in cardiovascular events has changed the policy argument. As more plans cover GLP-1s for cardiovascular prevention (not just obesity/diabetes), access will improve. Several major employers reversed GLP-1 exclusions in 2025 in response to employee demand.

But the full transition to broad, affordable insurance coverage is still a few years away for most patients.

In the meantime: document your medical history thoroughly, appeal denials, use HSA/FSA where available, and consider compounded alternatives if branded pricing is prohibitive.

Marrow can help you navigate the prior authorization process and provides documentation your insurance may require. And if insurance isn't viable, our compounded protocols start at $199/month with full physician oversight.